Semaglutide vs Tirzepatide vs Retatrutide
GLP-1 Receptor Agonist · Dual GIP/GLP-1 Receptor Agonist · Triple GIP/GLP-1/Glucagon Receptor Agonist
Here is how these two compounds compare, based on published research, not marketing claims.
Semaglutide
The established single-receptor GLP-1 agonist with the deepest evidence base and completed cardiovascular outcomes data.
Tirzepatide
The FDA-approved dual-receptor agonist (GIP and GLP-1) with the largest mean body weight reduction among approved medications.
Retatrutide
The investigational triple-receptor agonist (GIP, GLP-1, glucagon) with the largest weight reduction reported in any controlled trial; not yet FDA-approved.
Semaglutide
4520 studies
39 human trials
FDA-Approved
Tirzepatide
1849 studies
47 human trials
FDA-Approved
Retatrutide
131 studies
12 human trials
Not FDA-Approved
What it does
Semaglutide
Holds the first FDA approval for a weekly GLP-1 drug with cardiovascular outcomes data. Marketed as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet. Reduces appetite and slows how fast food leaves the stomach through hypothalamic GLP-1 receptor activation. Two major trials (SUSTAIN-6 in diabetic patients and SELECT in non-diabetic adults with obesity) showed reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death), not just weight or blood sugar. That cardiovascular evidence is what made the GLP-1 class category-shifting in metabolic medicine.
Tirzepatide
Activates two appetite-control receptors at once: GLP-1 and GIP. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound).
Retatrutide
A triple-receptor agonist studied for weight management and type 2 diabetes. Activates three appetite and metabolism receptors at once: GLP-1, GIP, and glucagon. Trial data shows the largest weight-loss effect of any peptide therapeutic published to date. Currently in Phase III development; not yet FDA-approved.
How it works
Semaglutide
A modified copy of GLP-1, a hormone the body releases naturally after eating. It activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas release insulin when blood sugar is high. The modification keeps it active in the body for about a week, instead of the few minutes natural GLP-1 lasts.
Tirzepatide
Engineered to bind two natural appetite hormones' receptors at once. The GLP-1 receptor tells the brain the body is full and slows stomach emptying (the same pathway as semaglutide). The GIP receptor adds enhanced fat oxidation and improved lipid metabolism. The dual signal does what GLP-1 alone does, plus the GIP component, which appears to drive the larger weight-loss effect. Like semaglutide, it stays active in the body for about a week, allowing once-weekly dosing.
Retatrutide
An engineered peptide that binds three receptor systems simultaneously. The GLP-1 side reduces appetite and slows gastric emptying (the mechanism semaglutide and tirzepatide use). The GIP side adds enhanced fat metabolism (the mechanism tirzepatide adds beyond GLP-1). The glucagon side adds increased energy expenditure and hepatic fat oxidation, the mechanism that distinguishes retatrutide from earlier GLP-1 medications. The combined triple action appears to drive the larger weight-loss numbers seen in published trials.
How often
Semaglutide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for the injectable formulation. The SUSTAIN, STEP, and SELECT trial protocols used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Semaglutide is marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral formulation for type 2 diabetes.
Tirzepatide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen. The SURPASS trial protocols (type 2 diabetes) and SURMOUNT trial protocols (chronic weight management) used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Retatrutide
Trial protocols across the TRIUMPH Phase III program use once-weekly subcutaneous injection. The TRIUMPH-4 trial ran 68 weeks; the Phase II obesity trial (Jastreboff et al. 2023, NEJM) ran 48 weeks; the Phase II type 2 diabetes trial (Rosenstock et al. 2023, Lancet) tested four ascending doses against placebo. Six remaining TRIUMPH Phase III trials are still reading out as of 2026. Retatrutide is not yet FDA-approved; clinical availability is restricted to investigational protocols.
How strong
Semaglutide
Strong appetite suppression. In the STEP obesity trials, average weight loss reached 15-17% at the highest dose over 68 weeks. The effect builds gradually as the dose titrates up over the first months of treatment.
Tirzepatide
The largest weight-loss effect of any FDA-approved peptide to date. In the SURMOUNT-1 trial, average weight loss reached 22.5% at the highest dose over 72 weeks. The effect builds as the dose titrates up.
Retatrutide
Phase II trials reported up to 24.2% mean body weight reduction at the 12 mg dose over 48 weeks (Jastreboff et al. 2023, NEJM). The TRIUMPH-4 Phase III trial reported 28.7% mean body weight reduction at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis, the largest weight-loss outcome reported in a controlled clinical trial. Six remaining TRIUMPH Phase III trials are still reading out across additional populations.
Main tradeoff
Semaglutide
Strong evidence base from large completed Phase III programs (STEP for weight, SUSTAIN and PIONEER for diabetes, SELECT for cardiovascular outcomes). Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide produces larger average weight loss in head-to-head trials, but semaglutide has the longer cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Tirzepatide
Larger average weight loss than semaglutide in head-to-head trials (SURPASS-2). Cardiovascular outcomes data is still maturing: semaglutide has SELECT, tirzepatide's parallel trial (SURPASS-CVOT) is ongoing. Less long-term safety data overall because tirzepatide is the newer of the two compounds. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Retatrutide
Trial data shows retatrutide producing larger mean body weight reduction than tirzepatide in Phase II indirect comparison and TRIUMPH-4 Phase III. The structural difference is FDA approval status: tirzepatide is FDA-approved and clinically available today; retatrutide remains in Phase III development. Less long-term safety data overall because the compound is the newer of the two. TRIUMPH-4 reported a new dysesthesia (abnormal skin sensation) safety signal at higher doses requiring monitoring across the remaining TRIUMPH program. Bone mineral density has not yet been reported in retatrutide trials; whether the class-shared bone-loss-with-weight-loss signal observed in semaglutide and tirzepatide users (Liu et al. 2026) extends to retatrutide is empirically open.
Best for
Semaglutide
- Adults with type 2 diabetes seeking glycemic control with cardiovascular outcomes data (SELECT trial)
- Adults with overweight or obesity who want the GLP-1 with the longest real-world safety record
- Clinical contexts prioritizing established cardiovascular outcomes over maximal weight reduction
Tirzepatide
- Adults with overweight or obesity seeking the largest average weight reduction available in trials
- Adults with type 2 diabetes seeking superior HbA1c reduction (SURPASS-2 head-to-head data)
- Clinical contexts willing to use a newer compound with less long-term safety data than semaglutide
Retatrutide
- Research interest in next-generation triple-receptor agonist mechanism
- Awaiting FDA approval for clinical use; monitoring the TRIUMPH Phase III program for population coverage and safety profile
- Patients in TRIUMPH or other retatrutide clinical trials under investigator supervision
How to choose
A good fit for Semaglutide
- Need an FDA-approved option with completed cardiovascular outcomes data (SELECT trial)
- Longest real-world safety record matters for clinical decision
- Single-receptor pharmacology with the most mature post-marketing surveillance
A good fit for Tirzepatide
- Need an FDA-approved option with the largest mean weight reduction among approved medications
- Dual-receptor mechanism (GIP plus GLP-1) for combined metabolic effect
- Available by prescription today with growing post-marketing record
A good fit for Retatrutide
- Research interest in the next-generation triple-receptor mechanism
- Monitoring the TRIUMPH Phase III program for clinical adoption when FDA approval lands
- Comfortable with the investigational status; not seeking a clinical option today
Consider all three
Three consecutive generations of incretin-based metabolic medications. Each adds a receptor: semaglutide activates GLP-1 alone; tirzepatide adds GIP; retatrutide adds glucagon on top of both. Weight loss magnitude increases with receptor breadth, but so does the evidence maturity gap. Semaglutide has the completed cardiovascular outcomes data that neither competitor has matched. Tirzepatide has the largest weight loss among FDA-approved options. Retatrutide has the largest weight loss in any published trial but remains investigational. For the pairwise comparison between the two FDA-approved options, see Semaglutide vs Tirzepatide. For the investigational comparison, see Tirzepatide vs Retatrutide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes; Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
Semaglutide activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full and slows how fast the stomach empties.
Tirzepatide activates both GLP-1 and GIP receptors at once. The GLP-1 side mirrors semaglutide; the GIP side adds enhanced fat metabolism.
Retatrutide activates three receptors at once: GLP-1, GIP, and glucagon. The glucagon side adds increased energy expenditure and hepatic fat oxidation.
Research Evidence
Semaglutide has the deepest evidence base: completed Phase III programs across diabetes (SUSTAIN, PIONEER), obesity (STEP), and cardiovascular outcomes (SELECT), with years of post-marketing surveillance. Tirzepatide has extensive Phase III data across SURPASS (diabetes) and SURMOUNT (obesity), with SURMOUNT-5 providing head-to-head data against semaglutide; cardiovascular outcomes trial ongoing. Retatrutide has Phase II data (Jastreboff 2023 NEJM) plus the first Phase III result (TRIUMPH-4, 2026) with six remaining TRIUMPH trials reading out. The evidence maturity gap narrows with each new trial but remains structurally large: semaglutide is the reference standard, tirzepatide is established but newer, retatrutide is investigational.
- 1.
If the priority is evidence maturity and long-term safety confidence, semaglutide has the deepest dataset and proven cardiovascular benefit.
- 2.
If the priority is maximal weight reduction with approved-status confidence, tirzepatide's SURMOUNT data represents the strongest outcome-to-maturity ratio.
- 3.
If the research interest is in next-generation multi-agonist mechanisms or hepatic fat reduction, retatrutide's triple-agonist approach is the most relevant, but results are investigational.
- 4.
For clinical decision-making today, only semaglutide and tirzepatide have the regulatory approval and evidence maturity to support prescribing decisions.
Key Limitations
- •Retatrutide's data comes from a single Phase II trial, results may not replicate in Phase III.
- •Cross-trial comparisons between compounds are inherently limited by differences in trial design, population, and endpoints.
- •The relationship between receptor count and clinical superiority is hypothesized, not proven.
- •Real-world adherence, cost, and access factors are not captured in clinical trial efficacy data.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Semaglutide
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Tirzepatide
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Retatrutide
"Retatrutide will make Ozempic and Mounjaro obsolete"
Plausible but premature
"The triple agonist mechanism is a game-changer"
Supported by evidence
"Retatrutide causes a weird tingling skin sensation"
Supported by evidence
Safety Comparison
All three share the GLP-1 class gastrointestinal side effect profile (nausea, vomiting, diarrhea, usually transient and dose-dependent). Semaglutide and tirzepatide carry the FDA boxed warning for thyroid C-cell tumors based on rodent studies. Semaglutide has the longest post-marketing safety record; tirzepatide's is growing since 2022 approval. Retatrutide's TRIUMPH-4 trial reported a new dysesthesia (abnormal skin sensation) safety signal at higher doses requiring continued monitoring. On bone density: semaglutide and tirzepatide users showed modest bone mineral density loss correlated with weight loss (Liu et al. 2026); whether this extends to retatrutide is empirically open given the larger weight-loss magnitude.
Semaglutide
Most mature safety dataset of the three. Multiple completed Phase III programs and years of post-marketing data. GI side effects are the primary tolerability concern.
Tirzepatide
Strong safety data from SURPASS and SURMOUNT programs. GI adverse events similar to GLP-1 agonists. Long-term data growing but less mature than semaglutide's.
Retatrutide
Phase II data shows a GI side-effect profile similar to other incretin-based peptides. The glucagon component introduces theoretical risks around blood glucose elevation and hepatic effects that require long-term monitoring. Phase III data not yet available.
What the Research Suggests
Semaglutide and tirzepatide are both clinically validated with strong evidence. Semaglutide offers the deepest safety confidence; tirzepatide offers the strongest weight-loss outcomes among approved agents. Retatrutide represents the next frontier in multi-agonist design, with early results that are compelling but investigational. The progression from single to triple agonism is scientifically significant, but evidence maturity must be weighed against mechanistic novelty. PSI rates semaglutide and tirzepatide at FDA Approved and retatrutide at Animal Studies, reflecting both the promise and the uncertainty of this evolving research space.